NCT05982925 Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
| NCT ID | NCT05982925 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 170 participants |
| Start Date | 2022-05-06 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 170 participants in total. It began in 2022-05-06 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this protocol, a combination of MRI, blood, and cerebrospinal fluid (CSF) analysis will be used to understand the natural history, underlying immunologic mechanisms, and clinical implications of central nervous system (CNS) lesions, in particular lesions in the cerebral cortex, in multiple sclerosis (MS) and other inflammatory and autoimmune disorders affecting the CNS. Patients with these disorders, as well as healthy controls, will undergo baseline clinical evaluation and testing, bloodwork, and MRI, with follow up clinical evaluation, bloodwork, and MRI at years 1, 3, and 6. Additional MRIs may be performed in patients with possible new lesion formation or to compare MRI techniques. Lumbar puncture will be performed on participants who are not currently being treated with disease modifying therapies and who are willing to undergo the procedure.
Eligibility Criteria
Inclusion Criteria: * 18 years old * able to provide consent in English * able to undergo MRI Exclusion Criteria: * contraindication to MRI * pregnancy
Contact & Investigator
Erin S Beck, MD, PhD
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT05982925 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05982925 currently recruiting?
Yes, NCT05982925 is actively recruiting participants. Contact the research team at erin.beck@mssm.edu for enrollment information.
Where is the NCT05982925 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05982925 clinical trial?
NCT05982925 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Erin S Beck, MD, PhD at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 170 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.